RMIT University
Browse

Supercomputing Multi-Ligand Modeling, Simulation, Wavelet Analysis and Surface Plasmon Resonance to Develop Novel Combination Drugs: A Case Study of Arbidol and Baicalein Against Main Protease of SARS-CoV-2

Download (8.18 MB)
journal contribution
posted on 2025-07-29, 02:16 authored by Hong Li, Hailong Su, Akari Komori, Shuxuan Yang, Hailang Luo, Angela Yang, Xiaomin Sun, Hong LiHong Li, Andrew Hung, Xiaoshan Zhao
<p dir="ltr">Background/Objectives: Combination therapies using traditional Chinese medicine and Western drugs have gained attention for their enhanced therapeutic effects and reduced side effects. Toujie Quwen Granules (TQG), known for its antiviral properties, particularly against respiratory viruses, could offer new treatment strategies when combined with antiviral drugs like arbidol, especially for diseases such as Coronavirus disease. This study investigates the synergistic mechanisms between arbidol and components from TQG against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro). </p><p dir="ltr">Methods: We identified compounds from TQG via existing data. Multi-ligand molecular docking, pharmacokinetic/toxicity screening, and preliminary simulations were performed to assess potential synergistic compounds with arbidol. UPLC-Q-Exactive Orbitrap-MS verified the presence of these compounds. Extended simulations and in vitro assays, including Luciferase and surface plasmon resonance, validated the findings. </p><p dir="ltr">Results: Five compounds interacted with arbidol in synergy based on docking and preliminary dynamics simulation results. Only Baicalein (HQA004) could be identified in the herbal remedy by untargeted metabolomics, with ideal pharmacokinetic properties, and as a non-toxic compound. Extended simulations revealed that HQA004 enhanced arbidol’s antiviral activity via a “Far” Addition Mechanism #2, with an optimal 2:1 arbidol:HQA004 ratio. The movements of arbidol (diffusion and intramolecular conformational shifts) in the system were significantly reduced by HQA004, which may be the main reason for the synergism that occurred. In vitro experiments confirmed an increased inhibition of Mpro by the combination. </p><p dir="ltr">Conclusions: HQA004 demonstrated synergistic potential with arbidol in inhibiting Mpro. The development of combination therapies integrating Western and herbal medicine is supported by these findings for effective antiviral treatments.</p>

Funding

Joint Funds of National Natural Science Foundation of China | U22A20365

National Natural Science Foundation of China (NSFC) | 82204812

National Natural Science Foundation of China (NSFC) | 82305059

Guangzhou Science and Technology Plan Project | 2024B03J1343

Major Scientific and Technological Project of Guangzhou Municipal Health Commission | 20252D003

China Postdoctoral Science Foundation | 2022M711534

Guangdong Basic and Applied Basic Research Foundation | 2021A1515110082

Guangdong Basic and Applied Basic Research Foundation | 2021A1515110711

History

Related Materials

  1. 1.
  2. 2.
    DOI - Is published in DOI: 10.3390/ph18071054
  3. 3.
    ISSN - Is published in 1424-8247 (Pharmaceuticals)

Journal

Pharmaceuticals

Volume

18

Number

1054

Total pages

34

Publisher

Multidisciplinary Digital Publishing Institute (MDPI)

Language

English

Copyright

© 2025 by the authors.

Open access

  • Yes

Usage metrics

    Scholarly Works

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC